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doi:10.101Graft-versus-Host disease Prophylaxis with Everolimus
and Tacrolimus Is Associated with a High Incidence of
Sinusoidal Obstruction Syndrome and
Microangiopathy: Results of the EVTAC Trial
Uwe Platzbecker, Malte von Bonin, Eray Goekkurt, Jo¨rgen Radke, Marc Binder,
Alexander Kiani, Jan Stoehlmacher, Johannes Schetelig, Christian Thiede,
Gerhard Ehninger, Martin Bornha¨userA calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease
(GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Everolimus, a derivative of siroli-
mus, seems to mediate antileukemia effects. We report on a combination of everolimus and tacrolimus in 24
patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n 5 17) or acute myeloid leu-
kemia (AML; n5 7) undergoing intensive conditioning followed by HSCT from related (n5 4) or unrelated
(n 5 20) donors. All patients engrafted, and only 1 patient experienced grade IV mucositis. Nine patients
(37%) developed acute grade II-IVGVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive
GVHD. Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of
acute renal failure. The study was terminated prematurely because an additional 6 patients (25%) developed
sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases. With a median follow-up of 26 months,
the 2-year overall survival rate was 47%. Although this new combination appears to be effective as a prophy-
lactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other
regimens.
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Beyond disease biology, the success of allogeneic
hematopoietic stem cell transplantation (HSCT) in
patients with hematologic malignancies is determined
mainly by the occurrence and extent of graft-versus-
host disease (GVHD) [1]. This is due to the close
link between the extent of GVHD and nonrelapse
mortality. In fact, patients who experience advanced
GVHD have mostly limited survival [2]. Conse-
quently, prevention of GVHD is the major goal and
primary challenge in clinical HSCT. Although numer-
ous trials have investigated various immunosuppres-edizinischeKlinik und Poliklinik I, Universita¨tsklinikum
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6/j.bbmt.2008.11.004sive drug combinations for GVHD prophylaxis,
cyclosporin A (CsA) and methotrexate has remained
the standard combination for more than 20 years [3].
The use of an alternative calcineurin inhibitor, tacroli-
mus, can significantly reduce acute, but not chronic,
GVHD [4,5]. Despite these treatments, however,
. 50% of patients who undergo HSCT develop clin-
ically significant GVHD. In addition, methotrexate is
highly toxic, inducing mucositis and delayed hemato-
poietic engraftment. Consequently, alternative immu-
nosuppressive drug combinations have been
investigated, including mycophenolate mofetil, but
none has produced significantly better results [6,7].
Sirolimus (rapamycin), first found on Easter Island
(RapaNui) as a naturally occurring compound isolated
from a soil saprophyte, belongs to a new generation of
immunosuppressive agents that inhibit themammalian
target of rapamycin (mTOR), an essential regulator of
cell cycle in proliferating T cells. Sirolimus and tacro-
limus (FK-506) act through different binding sites on
a transcription factor–binding protein, FKBP-12,
producing synergistic effects [8,9]. One advantage of
using a combination of sirolimus and tacrolimus101
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tochrome level. A combination of sirolimus and CsA
has been successfully used in patients after organ trans-
plantation [10] and with tacrolimus after allogeneic
matched related HSCT [11]. A short course of metho-
trexate was added in patients receiving grafts from
unrelated donors [12], resulting in low rates of acute
grade II-IV (26%) and chronic (42%) GVHD.
Recently, methotrexate was successfully omitted,
with no significantly change in the overall results [13].
Everolimus is a hydroxyethylester derivative of
sirolimus that has a shorter half-life (22 vs 72 hours)
and thus is more clinically manageable than sirolimus.
It has been successfully used in combination with CsA
after solid organ transplantation [14,15]. Like siroli-
mus [16,17], it exerts antiproliferative effects not
only in T cells, but also in malignant cells, which
theoretically could prevent disease recurrence after
allogeneic HSCT [18,19]. Tacrolimus appears to be
an ideal partner for everolimus in combination ther-
apy, because it has minimal effects on serum everoli-
mus levels compared with CsA. A pharmacokinetic
interaction between CsA and everolimus has been
described previously for healthy volunteers after
single-dose administration, presumably originating
from inhibition of hepatic cytochrome (CYP3A4) or
P-glycoprotein efflux transporter. As a result, a higher
dose of everolimus is needed in everolimus–tacrolimus
combination therapy (EVTAC) than in everolimus–
CsA combination therapy to achieve the desired ever-
olimus blood level [20]. Given the potential synergism
and favorable toxicity profile of EVTAC after alloge-
neic HSCT, we sought to investigate the efficacy of
this combination in patients with myelodysplastic syn-
drome (MDS) and acute myeloid leukemia (AML).METHODS
Study Design
The aim of this prospective pilot Phase II study
was to evaluate EVTAC in the setting of allogeneic
HSCT after busulfan-based intensive conditioning.
All patients provided written informed consent, and
the study design was approved by the local institutional
review board and the German Federal Administration.
Before recruitment, the study was registered at
www.clinicaltrials.gov as NCT00117702. The trial’s
primary endpoint was the incidence and severity of
acute GVHD, and secondary endpoints were the safety
and incidence of chronic GVHD and infectious com-
plications. A data safety monitoring board (DSMB)
was installed to review toxicities. Inclusion criteria
were hematologic malignancy, age 18 to 70 years,
and adequate liver, renal, cardiac, and pulmonary func-
tion conferring eligibility for intensive busulfan-based
conditioning. A patient could be included if a periph-eral blood stem cell donor (either related or unrelated)
with amaximumof 1 allele mismatch (9 out of 10) were
available. DNA-basedHLA typing of donor and recip-
ient was performed using intermediate resolution for
HLA class I (A, B, and C) and under high resolution
for HLA class II (DRB1 and DQB1).
Study Therapy
Tacrolimus was administered either i.v. at a dose of
0.03 mg/kg/day or as a bioequivalent oral dose in 2
divided doses starting on the day before HSCT (day
-1). The dose of tacrolimus was adjusted to maintain
blood levels between 5 and 10 ng/mL. Starting on
day 100 after HSCT, oral tacrolimus administration
was tapered by 5% each week if GVHD was inactive.
Everolimus was given orally starting on day 0 and
a starting dose of 1.5 mg/day in 2 divided doses. The
dose was subsequently adjusted to achieve a target
blood concentration between 3 and 8 ng/mL. Everoli-
mus administration was stopped on day 56 in the
absence of uncontrolled GVHD. Serum concentra-
tions of both drugs were obtained at least twice weekly.
Acute and chronic GVHDwere treated primarily with
prednisone.
Tests for cytomegalovirus (CMV) pp65 antigen or
polymerase chain reaction (PCR) for CMVDNAwere
performed weekly in patients at risk for CMV reactiva-
tion. In the event of a positive test result, preemptive
therapy with valganciclovir was initiated and adminis-
tered until day 100 or until PCR results were negative,
whichever occurred last. Prophylaxis against infectious
disease consisted of ciprofloxacin, fluconazole, and
acyclovir.
DNA Extraction and Genotyping
To detect single-nucleotide polymorphisms
(SNPs), DNA was extracted from whole blood using
the QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol
[21]. SNPs for glutathion-S-transferase (GST), such
as GSTP1-Ile105Val, GSTA1*a/b, and Cyp3A4*1B
polymorphisms, were detected by PCR–restriction
fragment length polymorphism analysis, and null ge-
notypes of GSTM1 and GSTT1 were detected by
multiplex PCR as described previously [22,23].
Samples were genotyped for Cyp3A4*3, Cyp3A5*2,
and Cyp3A5*3C polymorphisms (Cyp3A4*3: C_2753
5825_20, rs4986910; Cyp3A5*2: C_30633862_10,
rs28365083; Cyp3A5*3C: C_26201809_30, rs776746)
using a custom-designed system (Assay-on-Demand;
Applied Biosystems, Darmstadt, Germany). In brief,
a 10-ng DNA sample was added to a reaction volume
of 15 mL containing 7.5 mL of TaqMan Universal
PCR Master Mix, No AmpErase UNG, and 0.75 mL
of custom-designed probe. Amplifications were
performed on an Applied Biosystems 7500 real-time
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cles of 93C for 15 seconds and 60C for 1 minute.
Post-PCR plate reading was used to determine geno-
types. For quality control purposes, positive controls
of each genotype were used in each genotyping
approach.
Statistical Analyses
Overall survival and disease-free survival were ob-
tained by the Kaplan-Meiermethod, with patients cen-
sored at last follow-up if still alive [24]. The incidences
of relapse and nonrelapse mortality and GVHD were
calculated using cumulative incidence estimates [25].
Regimen-related toxicity was scored using the Com-
mon Toxicity Criteria (CTC), version 3.0 (National
Cancer Institute; available at (http://ctep.cancer.gov/
reporting/ctc.html). Acute and chronic GVHD were
diagnosed and graded using established criteria, with
a cutoff on day 100 after HSCT [26,27]. Smoothing
spline curve estimation techniques were used to fit
the trough serum levels of everolimus and tacrolimus
measured during the study period.RESULTS
Patient Characteristics
Between 2005 and 2008, a total of 24 patients with
MDS (n5 17, including 1 patient with therapy-relatedTable 1. Patient Characteristics and Outcome
UPN Age Disease
Previous
Treatment Karyotype IPSS HCT-CI Co
1262 58 RCMD Untreated Normal INT-1 0 Bu
1265 62 CMML-1 Untreated Normal INT-1 0 Bu
1267 67 RAEB-2 Untreated Complex HIGH 0 Bu
1269 47 RAEB-2 IC/1. PR Normal INT-1 0 Bu
1273 54 RCMD Untreated Complex INT-2 1 Bu
1283 63 RAEB-1 Decitabine/SD -7 INT-2 0 Bu
1301 61 RAEB-2 Untreated Complex HIGH 0 Bu
1303 55 AML IC/2. CR Normal/FLT3+ NA 1 Bu
1311 49 AML IC/1. CR Normal NA 0 Bu
1318 43 RCMD Untreated -7 INT-2 0 Bu
1324 54 RAEB-2 Untreated +13 HIGH 0 Bu
1331 62 AML IC/1. CR del(20q) NA 0 Bu
1333 50 tRAEB-1 Untreated Normal NA 3 Bu
1340 68 RAEB-2 Untreated Normal INT-2 1 Bu
1350 64 MDS/AML IC/1. CR Normal NA 0 Bu
1363 63 AML IC/2. CR inv16 NA 0 Bu
1416 69 RAEB-1 ATG/PD Normal INT-2 1 Bu
1475 66 CMML-2 Lenalidomide/PR del(5q) NA 0 Bu
1483 70 RAEB-2 Decitabine/SD t(1;3), 11q23 HIGH 1 Bu
1497 65 CMML-1 Untreated Normal NA 0 Bu
1502 67 AML IC/1. CR Complex NA 1 Bu
1519 62 RCMD Lenalidomide/CR Complex INT-2 0 Bu
1541 64 AML IC/1. PR Normal NA 0 Bu
1590 56 AML IC/1. CR Normal/FLT3+ NA 0 Bu
RCMD, refractory cytopenia with multilineage dysplasia; CMML, chronic myelo
remission; PR, partial remission; SD, stable disease; PD, progressive disease; t,
CI, hematopoietic stem cell transplantation comorbidity index [48]; Bu/Flu, bus
tion chemotherapy; NA, not applicable; ATG, antithymocyte globulin; PVT, po
*Due to stroke.
†DeathMDS [tMDS] 8 years after therapy for non-Hodgkin
lymphoma and 1 with AML evolving from MDS) or
de novo AML (n 5 7) were included in this trial.
The median patient age was 62 years (range, 47 to 70
years). Patient characteristics are summarized in Table
1. In 8 unrelated patient–donor pairs, a single-allele
HLA mismatch was accepted. Donors and patients
were sex-mismatched in 5 cases, with a female donor
for a male recipient in 2 cases. CMV seropositivity of
either donor or recipient was documented in 18
patients. All patients received granulocyte colony-
stimulating factor– mobilized peripheral blood stem
cells from related (n5 4) or unrelated (n5 20) donors
as described previously [28]. A median of 7.0  106/kg
CD341 cells (range, 3.0 to 9.6  106/kg) were trans-
planted.Engraftment
Rapid engraftment of neutrophils (median, 17
days; range, 11 to 20 days), defined as the first of 3 con-
secutive days of a neutrophil count . 0.5 Gpt/L, and
platelets (median, 15 days; range, 11 to 139 days),
defined as the first of 3 consecutive days of a platelet
count . 50 Gpt/L without platelet support, was
achieved in all patients. In 2 patients, however, platelet
counts dropped by more than half on days 37 and 40
after HSCT. At that time, neither elevated everolimus
serum trough levels nor transplantation-associatednditioning
Defibrotide
Prophylaxis
Liver
Toxicity TMA Status
Follow-Up,
Months
/Flu - SOS - Alive 32
/Flu - - - Alive 32
/Flu - - - Relapse 2†
/Flu - - - Alive 32
/Flu - - Yes TRM 3†
/Flu - - - Alive 31
/Flu - - Yes Relapse 3†
/Flu - - Yes TRM 15†
/Flu - SOS - Relapse 26†
/Flu - - - Alive 28
/Flu - - Yes TRM 7†
/Flu - - - Alive 27
/Flu - SOS - TRM 2†
/Flu - - - TRM 8†
/Flu - SOS - TRM 1†
/Flu - - - Alive 24
/Cy - - - Died* 19†
/Cy - SOS Yes Alive 15
/Cy - SOS - Alive 14
/Flu Yes - - Alive 13
/Flu Yes Hyperbilirubinemia - Relapse 3†
/Flu Yes - - TRM 5†
/Flu Yes PVT Yes Relapse 10
/Flu Yes - Yes Relapse 2†
monocytic leukemia; IPSS, International Prognostic Score; CR, complete
therapy-related; FLT3+, FLT3 internal tandem duplication positive; HCT-
ulfan and fludarabine; Bu/Cy, busulfan and cyclophopshamide; IC, induc-
rtal vein thrombosis; INT, intermediate.
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platelets recovered shortly after everolimus was
stopped.Dosage and Blood Trough Levels
During the first 56 days after HSCT, the median
daily dose was 1.5 mg for everolimus and 2 mg for
tacrolimus. Of note, all patients were able to take ever-
olimus orally during times of aplasia and rapidly
achieved the target blood concentrations of the study
drugs. Blood trough levels for both drugs over the first
60 days are provided in Figure 1. As shown, median
blood through levels for everolimus were 4.25 ng/
mL on day 3 and 5.6 ng/mL on day 9, and those for
tacrolimus were 7.65 ng/mL on day 3 and 7.5 ng/mL
on day 9. A few patients occasionally had levels below
or above the therapeutic serum level during the study
phase, but all returned promptly to the target level
after dose adjustment. But although everolimus was
scheduled to be administered up to day 56 after
HSCT, the drug actually was administered for only
a median of 44 days (range, 10 to 56 days). The reason
for premature discontinuation (required in 50% of
the patients) included early-onset (ie, day 6) GVHD-
associated hyperbilirubinemia, CTC grade 4 (n 5 1);
TMA (n 5 3); sinusoidal obstructive syndromeFigure 1. Everolimus and tacrolimus blood levels. The solid line is
a spline-smoothing curve. The everolimus and tacrolimus target ranges
were 5 to 10 ng/mL and 3 to 8 ng/ml (dashed lines), respectively.(SOS) of the liver (n 5 6); and at least a 50% drop in
platelet level after engraftment (n 5 2).
Infectious and Miscellaneous Complications
CMV-DNA or pp65 antigen was detectable in
only 9 of the 18 patients at risk (50%). Nonfatal
toxicities during aplasia included mucositis, CTC
grade I (n 5 6), II (n 5 7), III (n 5 10), or IV
(n 5 1), and neutropenic fever (n 5 13). Ten patients
developed diarrhea, CTC grade II (n 5 6) or III
(n 5 4), during conditioning-induced aplasia; 3 of
these patients had neutropenic enterocolitis. Two
patients developed hyperlipidemia, CTC grade II,
not requiring pharmacologic intervention.
Acute and Chronic GVHD
As shown in Figure 2, the cumulative incidences of
grade II-IV and grade III-IV acute GVHD were 38%
and 18%, respectively. Three of 4 patients with a re-
lated donor did not develop acute GVHD. Of 17
evaluable patients, 14 (82%) developed chronic
GVHD, 11 (65%) with an extensive form (Figure 3).
As of the time of this writing, 2 patients had been
able to discontinue immunosuppressive drug therapy.
Transplantation-Associated Microangiopathy
Decreased platelet counts with abnormally ele-
vated schistocyte levels, compatible with the recently
published criteria for TMA [29], was documented in
7 patients (29%), 2 of whom subsequently developed
acute renal failure. TMA was diagnosed a median of
32 days (range, 8 to 54 days) after HSCT. In 5 of the
7 patients with TMA, either tacrolimus (n 5 4) or
everolimus (n 5 1) blood trough levels were slightlyFigure 2. Cumulative incidence of acute GVHD in patients during
EVTAC prophylaxis.
Figure 3. Cumulative incidence of extensive chronic GVHD in 17
evaluable patients.
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the 2 patients with TMA associated with acute renal
failure, the EVTAC combination was replaced by
prednisone (2 mg/kg) and mycophenolate mofetil.
One patient subsequently developed grade IV acute
GVHD and died. In the remaining patients, TMA
was managed conservatively, including dose reduc-
tions of either tacrolimus or everolimus as appropriate.
Liver Toxicity
During aplasia (day 6), patient UPN 1502 devel-
oped hyperbilirubinemia, CTC grade IV, without as-
cites or weight gain (and thus not fulfilling the
criteria for SOS). Because this patient also had histo-
logically proven gut GVHD, compatible with early-
onset GVHD [30], the treating physicians decided to
switch the immunosuppressive therapy to CsA/myco-
phenolate mofetil plus prednisone (2 mg/kg/day).
Subsequently, the patient’s bilirubin levels normal-
ized.
SOS of the liver with hyperbilirubinemia, weight
gain, ascites, and subsequent increased serum creati-
nine level was observed in 6 patients (25%) a median
of 32 days (range, 10 to 51 days) after HSCT (Table
1). This was not associated with elevated blood
through levels of either tacrolimus or everolimus at
that time point. After SOS was found in 4 of the first
16 patients evaluated (including 2 who subsequently
died and 1 with tMDS), all of whom had been condi-
tioned with busulfan (3.45 mg/kg/day i.v. for 4 days
[days -6, -5, -4, and -3]) plus fludarabine (30 mg/m2
i.v. daily for 4 days [days -5 to -2]), as reported recently
[31,32], the DSMB decided to replace fludarabine with
cyclophosphamide (60 mg/kg i.v. on days -3 and -2),given the potential effects of fludarabine on liver endo-
thelial cells [33]. But even after this switch, 2 patients
of this series (UPN 1475 and UPN 1483) experienced
SOS (Table 1). Consequently, subsequent patients
were maintained on fludarabine and busulfan; how-
ever, during the time of combined EVTAC prophy-
laxis, defibrotide was administered prophylactically
(10 mg/kg/day), because of the protective effect dem-
onstrated in vitro [34] and in vivo [35]. Furthermore,
patient UPN 1541 also developed hyperbilirubinemia,
CTC grade IV, and complete thrombosis of the left
portal vein branch, as well as partial thrombosis of
the right branch, on day 34 after HSCT. Conse-
quently, given the occurrence of TMA despite defibro-
tide prophylaxis in patients UPN 1541 and 1590, the
DSMB decided to terminate the trial prematurely, cit-
ing safety issues, before reaching the target study pop-
ulation of 30 patients.
Association with Liver Toxicity and Metabolism
of Study Drugs
We investigated polymorphisms that could possi-
bly explain the high frequency of SOS seen in our study
population (see Methods). Genotyping of all of these
polymorphisms was performed successfully in all sub-
jects. Primarily, we explored whether SNPs of cyto-
chrome 3A5 and 3A4, being involved in the
metabolism of tacrolimus and everolimus, respectively
[20], could be attributed to the toxicity seen with this
regimen. All patients exhibited the wild type, however,
excluding the presence of ‘‘low metabolizers’’ as a rea-
son for the high incidence of SOS (data not shown).
Furthermore, analyses of polymorphisms of various
GSTs (GSTP1-Ile105Val, GSTA1*a/b, and null ge-
notypes of GSTM1 and GSTT1), which have been
linked to SOS [36], demonstrated no association with
the high incidence of SOS (data not shown).
Mortality, Relapse, and Survival
The day 100 and 1 year treatment-related mortal-
ity (TRM) rates were 12.5% and 29%, respectively. As
shown in Figure 4A, 7 patients died due to nonrelapse
mortality after a median of 165 days (range, 45 to 454
days), and 1 patient died due to apoplexia almost 2
years after HSCT. Hematologic relapse occurred in
6 of 24 patients (4 with AML, 2 with refractory anemia
with excess blasts (RAEB)-2), a median of 100 days
(range, 68 to 796 days) after HSCT (Figure 4B). All
but 1 patient (currently receiving reinduction) with re-
lapse died. With a median follow-up of 26 months for
surviving patients, the 2-year probabilities of overall
survival and disease-free survival were 47% and 37%,
respectively (Figure 5). There was no significant corre-
lation between overall or disease-free survival and host
CMV seropositivity, CD341 cell dose, age, or female
donor of a male host (data not shown).
Figure 4. Cumulative incidence of relapse (CI-R) and nonrelapse mor-
tality (CI-NRM) of the entire study cohort.
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The aim of this prospective trial was to study the
efficacy and toxicity of EVTAC as GVHD prophylaxis
after allogeneic HSCT. Although this combination
has been used successfully after renal transplantation
[37], data for HSCT are lacking. Overall, our findings
indicate some major problems and argue against the
feasibility of this approach in elderly patients receiving
intensive busulfan-based conditioning. The use of EV-
TAC in these patients was associated with a low inci-
dence of severe mucositis, and all of the patients
demonstrated rapid and stable engraftment; however,Figure 5. Probability of survival (A) and disease-free survival2 patients had a significant drop in platelets after initial
engraftment. This toxicity was not unexpected, given
the important function of mTOR in megakaryocytic
differentiation [38].
The rate of acute GVHD seen in this study seems
low given the high proportion of unrelated and even
mismatched donors. It compares quite well with that
reported by the Dana-Farber group [13] in their study
of tacrolimus and sirolimus combination therapy. But
the rate of extensive chronic GVHD appears to be as
high as that seen with other regimens, arguing against
a general protective effect of everolimus on GVHD. It
might be speculated that a longer administration of the
study drug could possibly overcome this problem;
however, this approach does not seem feasible, given
the toxicity profile in our patient cohort. In fact, half
of our patients had to stop everolimus before day 56
due to anticipated toxicities. Major concerns included
the high incidence of SOS of the liver, which exceeded
that generally reported in the literature (10%) [39],
as well as increased risk of toxicity in patients over
age 60 receiving ablative conditioning [40]. The reason
for these effects remains unclear, given that none of
our patients had received gemtuzumab ozogamicin
(which has been shown to increase the overall risk of
SOS [39]) before HSCT. Sirolimus has been shown
to induce thrombogenic alteration of endothelial cells
[41,42]. Interestingly, Cutler et al. [43] recently
reported an increased incidence of SOS with siroli-
mus-based GVHD prophylaxis compared with con-
ventional GVHD prophylaxis (15% vs 6%), although
this did not translate into worse patient outcomes.
Furthermore, SOS occurred later (median, 22 days vs
15 days), in line with our findings. Although no defin-
itive conclusions can be drawn from our small cohort,
it seems that the omission of fludarabine (which affects
liver sinusoidal and endothelial cells [33]) may abro-
gate the development of SOS with this regimen. Our
use of busulfan without total body irradiation for(B) of 24 patients with MDS or AML in the EVTAC trial.
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differences between our findings and those of others
[13]. Whether the use of targeted busulfan might
have altered the incidence of SOS within our protocol
remains to be studied. The presence of ‘‘low metabo-
lizers’’ was not a factor in the high incidence of SOS,
because SNPs of cytochrome 3A4 and 3A5 were not
present. This is important, because cytochrome 3A4
is involved in the metabolism of everolimus, and
cytochrome 3A5 is involved in the metabolism of
tacrolimus [44,45]. The null genotype of GSTM1
predisposes children with thalassemia undergoing
busulfan-based allogeneic HSCT to SOS [36]; how-
ever, analyses of these and further polymorphisms of
various GSTs revealed no explanation for the high
incidence of SOS observed in our study population.
We are also concerned about the frequency of
TMA in our trial, which is higher compared with the
Dana-Farber experience with a sirolimus-tacrolimus
combination [13]. However, recent data from a Seattle
study [46] are compatible with our observations and,
together with experience in the treatment of steroid-
refractory GVHD [47], suggest that mTOR inhibition
might increase the overall risk of TMA. Cutler et al.
[13] found that TMA could be overcome by dose
reduction or cessation of tacrolimus in all cases.
Together with our observation that TMA was associ-
ated mainly with slightly increased tacrolimus levels,
this suggests that everolimus increases the potential
of tacrolimus to induce TMA in transplant recipients.
In summary, use of the EVTAC combination for
GVHD prophylaxis is associated with significant
toxicity and thus does not seem to improve overall out-
come. For this reason, this combination cannot be
recommended as a prophylactic regimen after busul-
fan-based intensive conditioning. Future studies in
the context of total body irradiation–based or
reduced-intensity conditioning regimens might reach
a different conclusion, however.ACKNOWLEDGMENTS
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